Director Raymond Anderson of Monopar Therapeutics (NASDAQ:MNPR) filed a Form 4 on November 4, 2026, disclosing option exercises and open-market share sales executed on November 2, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercise (first grant): Anderson exercised stock options covering 1,402 shares at an exercise price of $29.9986, originally granted September 18, 2017.
  • Option exercise (second grant): Anderson exercised stock options covering 1,740 shares at an exercise price of $30.00, originally granted August 9, 2018.
  • Shares sold: A total of 3,142 shares of common stock were disposed of across four sale tranches at weighted average prices ranging from $66.16 to $70.04 per share.
  • Remaining beneficial ownership: Following all reported transactions, Anderson directly owned 5,373 shares of common stock.
  • 10b5-1 plan: The transactions were effected pursuant to a Rule 10b5-1 plan executed by Anderson on May 26, 2026.
  • Remaining options: After the exercises, Anderson held 1,401 options with an expiration of September 17, 2027, and 1,740 options expiring August 8, 2028.

Anderson's November 2 Option Exercises and Sales at Monopar Therapeutics

According to the filing, Director Raymond Anderson exercised two tranches of stock options on November 2, 2026. The first tranche covered 1,402 shares at $29.9986, drawn from a September 18, 2017 grant of up to 4,205 shares that vested at a rate of 6/42nds at the six-month anniversary of the grant date and 1/42nd per month thereafter. The second tranche covered 1,740 shares at $30.00, drawn from an August 9, 2018 grant of up to 5,220 shares that vested 20% on each of five dates between January 1, 2019 and January 1, 2020, the filing stated.

Following the exercises, the filing disclosed four separate sale transactions, all on November 2, 2026. Anderson sold 840 shares at a weighted average price of $66.16 (range $65.56 to $66.53), 600 shares at $67.06 (range $66.88 to $67.57), 200 shares at $68.68 (range $68.59 to $68.77), and 1,502 shares at $70.04 (range $70.02 to $70.32). All weighted average prices reflect multiple transactions within the stated ranges, and the filing noted that Anderson undertakes to provide full price-by-price detail upon request to Monopar Therapeutics, any security holder, or SEC staff.

All transactions were carried out under a Rule 10b5-1 trading plan that Anderson established on May 26, 2026, the filing stated. After all reported activity, Anderson's direct beneficial ownership of common stock stood at 5,373 shares, according to the filing. The form was signed by Quan Vu as attorney-in-fact on November 4, 2026.

What Was Disclosed

The Form 4 filed November 4, 2026, reported that Director Raymond Anderson exercised options on 3,142 shares and sold those same 3,142 shares in four tranches on November 2, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 5,373 directly held shares.